-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Unite Hearts and Focus Efforts to Secure Victory in 2026 | Keyuan Pharmaceutical & Linuo Pharmaceutical Hold a 2025 Marketing Summary and 2026 First-Quarter Kickoff Meeting
Publish Time:
2026-01-03
The first-quarter bugle has sounded, and the drums of marketing are resounding throughout the land. On January 3, Keyuan Pharmaceutical (stock code: 301281.SZ) and Linuo Pharmaceutical successfully held their 2025 Marketing Summary Meeting and 2026 First-Quarter Kickoff Rally. Centered around the theme “Reviewing the Past, Seizing the First Quarter,” the meeting comprehensively summarized past achievements, set its sights on securing a strong start to the first quarter, and aimed to achieve new growth for the entire year.
The first-quarter bugle has sounded, and the drums of marketing are resounding throughout the land. On January 3, Keyuan Pharmaceutical (stock code: 301281.SZ) and Linuo Pharmaceutical successfully held their 2025 Marketing Summary Meeting and 2026 First-Quarter Kickoff Rally. Centered around the theme “Reviewing the Past, Seizing the New Beginning,” the meeting comprehensively summarized past achievements, set its sights on securing a strong start to the first quarter, and aimed to achieve new growth for the entire year.
Li Hongfu, Chairman of Keyuan Pharmaceutical, Gao Chunpo, President, along with marketing executives from both companies and representatives from all core departments, attended the meeting and set off fully prepared.
Keyuan Pharmaceutical Conducts a Comprehensive Post-Mortem Analysis and Makes Precise Strategic Moves.
The conference was held simultaneously in two venues. The Keyuan Pharmaceutical venue kicked off with the performance of “The Song of Linuo” and a recitation of the company’s corporate culture, setting an inspiring tone for a comprehensive marketing review. The Sales Management Department, various API business units, regional marketing teams, and branch offices in Shanghai and Guangzhou successively took the stage to conduct in-depth analyses of the 2025 target achievement and market dynamics. At the same time, the focus shifted to the full-year and first-quarter targets for 2026, breaking down the first-month tasks into a three-dimensional grid—covering “products, regions, and personnel”—to ensure clear accountability and effective implementation.
Linuo Pharmaceutical: Focusing deeply, pooling strengths, and tackling challenges head-on.
The LiNuo Pharmaceutical conference venue saw a steady rise in momentum, focusing on three core areas: “data review and analysis, business unit planning, and sales and marketing empowerment.” The event featured ten agenda items aimed at tackling key challenges in depth. From a comprehensive overview of 2025 marketing data to annual summaries and New Year plans for six major business units—including medical, retail, and commercial sectors—and practical sales and marketing skills training, each segment’s reports directly addressed specific goals and provided precise breakdowns. Monthly targets and key product assignments were firmly assigned to each provincial region and frontline business teams, clearly defining critical actions for customer acquisition and channel development.
Chairman Li Hongfu fully affirmed the hard-won achievements made by Keyuan Pharmaceutical and Linuo Pharmaceutical in 2025, and guided by the principle of “precise breakthroughs and collaborative advancement,” he called on all employees to adopt a vigorous and proactive attitude—“start with full speed and treat the opening phase as a decisive battle”—to ensure a strong start in the first quarter of 2026. Based on a systematic summary of the practical experiences from 2025, the conference further clarified the strategic growth path for 2026: “centering on products, leveraging channels as the backbone, and building a solid foundation on our team.”
As the wind rises and sails are hoisted, battle flags flutter in the breeze. All staff members of Keyuan Pharmaceutical and Linuo Pharmaceutical will take this conference as a starting point, vowing to adopt the pioneering spirit of “breaking new ground wherever we encounter mountains and building bridges wherever we meet water,” as well as the tenacious perseverance of “clinging firmly to the green hills and working steadily over the long haul.” We will go all out to win the crucial battle in the first quarter and secure new victories for the entire year of 2026!
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline